blood drugs and diabetes drugs - names and mechanisms

STUDY
PLAY

Terms in this set (...)

heparin
antithrombin activator
warfarin
interference with y carboxylation 2, 7, 9, 10, C, S
apixaban
direct factor Xa inhibitor
rivaroxaban
direct factor Xa inhibitor
alteplase
thrombolytic (plasminogen --> plasmin)
reteplase
thrombolytic (plasminogen --> plasmin)
streptokinase
thrombolytic (plasminogen --> plasmin)
tenecteplase
thrombolytic (plasminogen --> plasmin)
aspirin
COX inhibitor
clopidogrel
ADP receptor inhibitor (P2Y12 inhibitor)
prasugrel
ADP receptor inhibitor (P2Y12 inhibitor)
ticagrelor
ADP receptor inhibitor (P2Y12 inhibitor)
ticlopidine
ADP receptor inhibitor (P2Y12 inhibitor)
cilostazol
PDE 3 inhibitor
dipyradimole
PDE 3 inhibitor
abciximab
GP 2b/3a inhibitor
eptifibatide
GP 2b/3a inhibitor
tirofiban
GP 2b/3a inhibitor
metformin
biguanide
unknown mechanism, increases insulin sensitivity
biguanides (metformin)
chlorpropamide
sulfonylurea
tolbutamide
sulfonylurea
glimepiride
sulfonylurea
glipizide
sulfonylurea
glyburide
sulfonylurea
pioglitazone
thiazolidinedione
rosiglitazone
thiazolidinedione
exenatide
GLP1 analog
liraglutide
GLP1 analog
linagliptin
DPP4 inhibitor
saxagliptin
DPP4 inhibitor
sitagliptin
DPP4 inhibitor
pramlintide
amylin analog
canagliflozin
SGLT2 inhibitor
acarbose
a-glucosidase inhibitor
miglitol
a-glucosidase inhibitor
close K channels in B cell membrane --> cell depolarizes --> insulin release via Ca2+ influx
sulfonylureas
increase insulin sensitivity via binding to PPAR-y transcription regulator
thiazolidinediones
increase insulin and decrease glucagon release
GLP1 analogs, DPP4 inhibitors
decrease gastric emptying, decrease glucagon
amylin analogs
block reabsorption of glucose in PCT
SGLT2 inhibitors
inhibit intestinal brush border a-glucosidases, delayed carbohydrate hydrolysis and glucose absorption --> decreased postprandial hyperglycemia
a-glucosidase inhibitors